Please assess the completion status of the following clinical trial:

Trial Title: GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria.~* Have active SLE disease.~* Have positive anti-nuclear antibody (ANA) test results.~* Are on a stable SLE treatment regimen.~* Females of childbearing age are willing to use appropriate contraception~Exclusion Criteria:~* Have received treatment with any B cell targeted therapy at any time.~* Have received a biologic investigational agent in the past year.~* Have received 3 or more courses of systemic corticosteroids in the past year.~* Have received intravenous (IV) cyclophosphamide within 180 days prior to Day 0.~* Have severe lupus kidney disease.~* Have active central nervous system (CNS) lupus.~* Have had a major organ transplant.~* Have significant unstable or uncontrolled acute or chronic diseases or conditions not due to SLE.~* Have a planned surgical procedure.~* Cancer within the last 5 years, except for adequately treated skin cancer, or carcinoma in situ of the uterine cervix.~* Have required management of acute or chronic infections in the past 60 days.~* Have current drug or alcohol abuse or dependence.~* Have a historically positive test, or test positive at screening for HIV, Hepatitis B, or Hepatitis C.~* Have an IgA deficiency.~* Have severe laboratory Abnormalities.~* Have had anaphylactic reaction to X-ray contrast agents or biologic agents.~* Suicidal behavior or ideation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab (Type: EXPERIMENTAL): 10mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).